Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to prepare the health system for the forecasted increase in the eligible radioligand therapy patient population.

It is expected that all new therapeutic radioligand treatments for cancer will be appraised by National Institute of Health and Care Excellence (NICE), via its technology appraisal process. If approved, treatments are normally made available to patients from the date of NICE’s positive draft guidance. National Health Service regional teams would commission providers to deliver radioligand therapy based on an assessment of current access arrangements, current and future demand and whether the provider can meet the required standards.